Harvard Bioscience's total inventories for the quarter that ended in Mar. 2026 was €19.21 Mil. Harvard Bioscience's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was €18.49 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Harvard Bioscience's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was €-7.43.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Harvard Bioscience's Days Inventory for the
three
months ended in Mar. 2026 was 229.14.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Harvard Bioscience's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.40.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Harvard Bioscience's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 1.03.
Harvard Bioscience (FRA:HBI0) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Harvard Bioscience's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Harvard Bioscience's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Harvard Bioscience Total Inventories Related Terms
Harvard Bioscience Total Inventories Historical Data
* Premium members only.
The historical data trend for Harvard Bioscience's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Harvard Bioscience (FRA:HBI0) has a Total Inventories of €19.21 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Harvard Bioscience and its competitors.
Is Harvard Bioscience's Total Inventories too high?
Harvard Bioscience's current Total Inventories is €19.21 Mil. Overall, Harvard Bioscience has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Harvard Bioscience's Total Inventories compare to FEMY and RVP?
Harvard Bioscience's Total Inventories of €19.21 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Medical Devices & Instruments company?
A good Total Inventories depends on the Medical Devices & Instruments industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Harvard Bioscience and its competitors. Harvard Bioscience's current Total Inventories is €19.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Bioscience stock overvalued right now?
Harvard Bioscience (FRA:HBI0) has a current Total Inventories of €19.21 Mil. The stock's GF Value™ is €13.30, compared to a current price of €4.08 — trading 69.3% below its estimated fair value. The current Total Inventories is €19.21 Mil. Harvard Bioscience's overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Harvard Bioscience (FRA:HBI0), the current Total Inventories is €19.21 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harvard Bioscience (FRA:HBI0) Overvalued in 2026?
Based on GuruFocus' analysis, Harvard Bioscience stock appears to be undervalued.
The current stock price of €4.08 is trading 69.3% below its estimated GF Value™ of €13.30.
Key valuation signals for FRA:HBI0:
Total Inventories: €19.21 Mil
GF Value™: €13.30 vs. price of €4.08 (69.3% below fair value)
No single metric tells the full story. See the FRA:HBI0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
48GF Score
Get the complete analysis for FRA:HBI0
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HBI0 has been successfully added to your 
